Proudly Supported by
With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher…
